GC Genome Corporation (KOSDAQ: A340450)
Health Care · Biotechnology · KR
₩5,620.00
+2.74% today · -27.3% 1Y
GC Genome Corporation (KOSDAQ: A340450) operates in the Biotechnology industry within the Health Care sector. The company is valued at $94.03M.
Over the last twelve months the share price has lost 27.3%, trading between 4.10K and 9.52K.
Tweenvest scores GC Genome Corporation across four factors: quality 65/100, value 64/100, growth 75/100. Its strongest factor is growth.
A340450 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $94.03M
- Revenue (TTM)
- $21.12M
- P/E
- 28.19
- EPS
- 199.37
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- ₩9,520.00
- 52-week low
- ₩4,100.00
- Avg volume (3M)
- —
- Shares outstanding
- 23.65M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.85 | -1.11% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.11 | -0.48% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.03 | -0.50% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.73 | -0.56% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $818.74 | -1.78% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $148.45 | -6.54% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.